Bcpps Practice Questions Set #1 Exam Questions And Answers 2024.

The pharmacy and therapeutics (P&T) committee at a children's hospital is reviewing an application to add an antimicrobial agent that is active against highly resistant gram-negative bacteria and has new data for use in children. There is a desire to add this medication to formulary, but there are concerns about resistance development to this medication, which has occurred in adult populations. Which strategy is best for adding this medication to formulary? a. Maintain the antibiotic as a non-formulary product to discourage use except in emergencies. b. Add the antibiotic to the formulary with no additional restrictions. c. Add the antibiotic to the formulary, but restrict its use in the pediatric intensive care unit (ICU). d. Add the antibiotic to the formulary, but restrict its use to the infectious disease service. d. Add the antibiotic to the formulary, but restrict its use to the infectious disease service. Which is most likely to ensure change in practice or processes after completing a medication use evaluation (MUE)? a. Adult and pediatric populations are assessed using the same outcomes. b. A multidisciplinary team of key stakeholders participates. c. High-cost medications are evaluated. d. The scope of the evaluation is expanded once data collection begins. b. A multidisciplinary team of key stakeholders participates. Which best describes inventory practices that should be used during a drug shortage? a. Drug supply should be obtained by any means possible, including "gray market" or compounding sources. b. The decision to use "gray market" or compounding sources should be made before critical supply levels are reached. c. When supply is available, the pharmacists responsible for inventory should order as much as possible, regardless of use history. d. The pharmacy should order alternative non- formulary products before a multidisciplinary review of need for alternatives. b. The decision to use "gray market" or compounding sources should be made before critical supply levels are reached. An MUE is being undertaken to help ensure that prescribers in the outpatient setting are following the Risk Evaluation and Mitigation Strategies (REMS) for mycophenolate mofetil and pregnancy. Which step should be taken first? a. Identify the pediatric and adult outpatient areas in which females of childbearing age are prescribed mycophenolate to determine the scope of the evaluation. b. Discuss requirements for contraception and pregnancy testing with the family advisory committee to determine how patients and families will best receive education. c. Discuss which outcome measures related to pregnancy test frequency and contraception counseling are most appropriate for this MUE. d. Develop a protocol for pregnancy testing for females of childbearing age to ensure compliance with the REMS program. a. Identify the pediatric and adult outpatient areas in which females of childbearing age are prescribed mycophenolate to determine the scope of the evaluation. Which best illustrates a potential barrier faced by a pediatric pharmacist when providing care to pediatric patients? a. A formulary diuretic is available both as tablets and as an oral liquid suspension. b. A hospital uses a standardized dosing nomogram for acetaminophen oral liquid suspension. c. A pump for subcutaneous treprostinil cannot accurately deliver the initial starting dose in an infant. d. The safety and efficacy of off-label use of a new sedative in a pediatric ICU patient is supported by an available prospective study. c. A pump for subcutaneous treprostinil cannot accurately deliver the initial starting dose in an infant. Which strategy can best help ensure the safe provision of pharmacy services for pediatric inpatients? a. Dispensing patient-specific dilutions as determined by the Rule of 6. b. Dispensing multidose products, such as a reconstituted bottle of amoxicillin suspension. c. Purchasing products with preservatives like benzyl alcohol, when possible. d. Avoiding the use of high-osmolarity products in peripheral lines. d. Avoiding the use of high-osmolarity products in peripheral lines. Pediatric pharmacists providing pharmacy services in an outpatient care setting should have an understanding of the unique medication needs of patients and their caregivers. Which would be considered the most essential component in providing outpatient services to pediatric patients and their caregivers? a. Educating pediatricians on poison prevention. b. Providing drug information education for nurses and providers. c. Educating caregivers on accurate medication measurement. d. Knowing what medication preparations are commercially available. c. Educating caregivers on accurate medication measurement. Which best describes the location and maximum volume that should be used for an intramuscular injection in a neonate? a. Deltoid, 0.5 mL. b. Deltoid, 1 mL. c. Vastus lateralis, 0.5 mL. d. Vastus lateralis, 1 mL. c. Vastus lateralis, 0.5 mL. 3: vastus lateralis 3: deltoid, vastus lateralis Older children: deltoid, ventral gluteal region Small infant: 0.5 mL Older infant/toddler: 1 mL School-aged child: 2 mL Adolescent: 3 mL Which best describes a challenge faced when adapting adult electronic health records (EHRs) for use in pediatric patients? a. Fewer dosage forms and concentrations are needed. b. All products used in pediatric patients have manufacturer barcodes available for scanning. c. Chronological age is appropriate for all patients when designing dosing algorithms. d. Rounding algorithms can cause inappropriate dosing in neonates. d. Rounding algorithms can cause inappropriate dosing in neonates. Smart infusion pumps help enhance the safe delivery of intermittent and continuous-infusion parenteral medications. Pediatric pharmacists should be highly involved in developing the drug library content for these pumps. Which would best be routinely assessed to optimize the infusion pump library? a. Unnecessary alerts. b. Need to develop new workarounds. c. Nurses' inclination to use library. d. Changes to dosing in library according to new guidelines. a. Unnecessary alerts. A joint task force created by the American College of Clinical Pharmacy (ACCP) and the Pediatric Pharmacy Advocacy Group (PPAG) developed strategies to expand the quality and capacity of clinical pharmacy services provided to pediatric patients. Which strategy would best enhance clinical pharmacy services? a. Developing minimum expectations for the training of those entering pediatric practice. b. Substituting on-the-job training for postgraduate year two (PGY2) residency experience. c. Expanding the service coverage of currently available clinical pharmacy specialists. d. Developing expectations for the participation of clinical pharmacists in pediatric research. a. Developing minimum expectations for the training of those entering pediatric practice. In the pediatric population, a unilateral approach to quality assessment in pediatric health care is likely to be unsuccessful. Which is most likely to complicate a unilateral approach in pediatric patients? a. Communication barriers. b. Heterogeneity of the population. c. Patient independence. d. Availability of health insurance. b. Heterogeneity of the population. Which best describes the purpose of the core set established by the Children's Health Insurance Program (CHIP) Reauthorization Act? a. To assess the quality of care provided to children by a health system. b. To assess the quality of care provided to children within various private insurance programs. c. To assess the quality of care provided to children within Medicaid/CHIP. d. To assess the quality of care provided to children by community health offices. c. To assess the quality of care provided to children within Medicaid/CHIP. You are the pediatric pharmacy representative to the P&T committee for a health system that provides care to both pediatric and adult patients. Acid-suppressive therapies are being reviewed as a cost-saving initiative. You receive the formulary monograph for the histamine-2 receptor antagonists to review before the upcoming meeting. The recommendation is to maintain one intravenous and enteral agent for use in all age groups, but no pediatric data or assessments of available dosage forms are included. Which is the best next step to ensure that the recommendation presented in the monograph to the P&T committee is complete and accurate for the pediatric patients cared for by the health system? a. Gather input from key pediatric stakeholders regarding the recommendations for medications from this class that should be placed on the formulary for pediatric patients. b. Identify and evaluate available pediatric pharmacoki b. Identify and evaluate available pediatric pharmacokinetic, safety, and outcomes data for the class of medications to make recommendations for updating the monograph.